Methadone in Post-Herpetic Neuralgia Pain

University of Sao Paulo10 enrolled

Overview

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Post-herpetic Neuralgia

Interventions

MethadoneDRUG

patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.

PlaceboDRUG

patients with post-herpetic neuralgia take placebo to treat the pain symptoms.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with chronic (\>6 months) symptomatic PHN * with visual analogical scale \>40/100mm * use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids) Exclusion Criteria: * Don't full the criteria above

Outcomes

Primary Outcomes

Change in baseline Pain

Assessing by verbal analog scale (VAS)

Time frame: baseline (visit inclusion) and three moths latter

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.